Search

Your search keyword '"Echenique LS"' showing total 9 results
Start Over Author "Echenique LS"
9 results on '"Echenique LS"'

3. Poster session 4: Friday 5 December 2014, 08:30-12:30 * Location: Poster area

Author

Orii, M, Tanimoto, T, Yokoyama, M, Ota, S, Kubo, T, Hirata, K, Tanaka, A, Imanishi, T, Akasaka, T, Michelsen, MM, Pena, A, Mygind, ND, Hoest, NB, Prescott, E, Abd El Dayem, SOHA, Battah, AHMED, Abd El Azzez, FATEN, Ahmed, AZZA, Fattoh, AYA, Ismail, REEM, Andjelkovic, K, Kalimanovska Ostric, D, Nedeljkovic, I, Andjelkovic, I, Rashid, HESHAM, Abuel Enien, HESHAM, Ibraheem, MAHER, work, Tissue Doppler echocardiography research, Vago, H, Toth, A, Csecs, I, Czimbalmos, CS, Suhai, F I, Kecskes, K, Becker, D, Simor, T, Merkely, B, D'ascenzi, F, Pelliccia, A, Natali, BM, Cameli, M, Lisi, M, Focardi, M, Corrado, D, Bonifazi, M, Mondillo, S, Zaha, VG, Kim, GE, Su, KN, Zhang, J, Mikush, N, Ross, J, Palmeri, M, Young, LH, Tadic, M, Ilic, SI, Celic, VC, Jaimes, C, Gonzalez Mirelis, J, Gallego, M, Goirigolzarri, J, Pellegrinet, M, Poli, S, Prati, G, Vriz, O, Di Bello, V, Carerj, S, Zito, C, Mateescu, A, Popescu, BA, Antonini-Canterin, F, Chatzistamatiou, E, Moustakas, G, Memo, G, Konstantinidis, D, Mpampatzeva Vagena, I, Manakos, K, Traxanas, K, Vergi, N, Feretou, A, Kallikazaros, I, Hewing, B, Theres, L, Dreger, H, Spethmann, S, Stangl, K, Baumann, G, Knebel, F, Uejima, T, Itatani, K, Nakatani, S, Lancellotti, P, Seo, Y, Zamorano, JL, Ohte, N, Takenaka, K, group, VFM international collaboration, Naar, J, Mortensen, L, Johnson, J, Winter, R, Shahgaldi, K, Manouras, A, Braunschweig, F, Stahlberg, M, Coisne, D, Al Arnaout, A-M, Tchepkou, C, Raud Raynier, P, Diakov, C, Degand, B, Christiaens, L, Barbier, P, Mirea, O, Cefalu, C, Savioli, G, Guglielmo, M, Maltagliati, A, O'neill, L, Walsh, K, Hogan, J, Manzoor, T, Ahern, B, Owens, P, Savioli, G, Guglielmo, M, Mirea, O, Cefalu, C, Barbier, P, Sengelov, M, Biering-Sorensen, T, Jorgensen, PG, Bruun, NE, Fritz-Hansen, T, Bech, J, Olsen, FJ, Sivertsen, J, Jensen, JS, Marta, L, Abecasis, J, Reis, C, Ribeiras, R, Andrade, MJ, Mendes, M, D'andrea, A, Stanziola, A, Di Palma, E, Martino, M, Lanza, M, Betancourt, V, Maglione, M, Calabro', R, Russo, MG, Bossone, E, Vogt, M O, Meierhofer, CH, Rutz, TH, Fratz, S, Ewert, P, Roehlig, CH, Kuehn, A, Storsten, P, Eriksen, M, Remme, EW, Boe, E, Smiseth, OA, Skulstad, H, Ereminiene, E, Ordiene, R, Ivanauskas, V, Vaskelyte, J, Stoskute, N, Kazakauskaite, E, Benetis, R, Marketou, M, Parthenakis, F, Kontaraki, J, Zacharis, E, Maragkoudakis, S, Logakis, J, Roufas, K, Vougia, D, Vardas, P, Dado, E, Dado, E, Knuti, G, Djamandi, J, Shota, E, Sharka, I, Saka, J, Halmai, L, Nemes, A, Kardos, A, Neubauer, S, Kurnicka, K, Domienik-Karlowicz, J, Lichodziejewska, B, Goliszek, S, Grudzka, K, Krupa, M, Dzikowska-Diduch, O, Ciurzynski, M, Pruszczyk, P, Chung, H, Kim, JY, Yoon, YW, Min, PK, Lee, BK, Hong, BK, Rim, SJ, Kwon, HM, Choi, EY, Soya, OV, Kuryata, OV, Kakihara, R, Naruse, C, Inayoshi, A, El Sebaie, MAHA, Frer, ABDEL, Abdelsamie, MAGDY, Eldamanhory, AHMED, Ciampi, Q, Cortigiani, L, Simioniuc, A, Manicardi, C, Villari, B, Picano, E, Sicari, R, Ferferieva, V, Deluyker, D, Lambrichts, I, Rigo, JM, Bito, V, Kuznetsov, VA, Yaroslavskaya, EI, Krinochkin, DV, Pushkarev, GS, Gorbatenko, EA, Trzcinski, P, Michalski, BW, Lipiec, P, Szymczyk, E, Peczek, L, Nawrot, B, Chrzanowski, L, Kasprzak, JD, Todaro, MC, Zito, C, Khandheria, BK, Cusma-Piccione, M, La Carrubba, S, Antonini-Canterin, F, Di Bello, V, Oreto, G, Di Bella, G, Carerj, S, Gunyeli, E, Oliveira Da Silva, C, Sahlen, A, Manouras, A, Winter, R, Shahgaldi, K, Spampinato, RA, Tasca, M, Roche E Silva, JG, Strotdrees, E, Schloma, V, Dmitrieva, Y, Dobrovie, M, Borger, MA, Mohr, FW, Einarsen, E, Cramariuc, D, Lonnebakken, MT, Boman, K, Gohlke-Barwolf, C, Chambers, JB, Gerdts, E, Calin, A, Rosca, M, Beladan, CC, Mirescu Craciun, A, Gurzun, MM, Mateescu, A, Enache, R, Ginghina, C, Popescu, BA, Antova, E, Georgievska Ismail, LJ, Srbinovska, E, Andova, V, Peovska, I, Davceva, J, Otljanska, M, Vavulkis, M, Tsuruta, H, Kohsaka, S, Murata, M, Yasuda, R, Dan, M, Yashima, F, Inohara, T, Maekawa, Y, Hayashida, K, Fukuda, K, Migliore, R, Adaniya, ME, Barranco, MA, Miramont, G, Gonzalez, S, Tamagusuku, H, Abid, L, Ben Kahla, S, Charfeddine, S, Abid, D, Kammoun, S, Amano, M, Izumi, C, Miyake, M, Tamura, T, Kondo, H, Kaitani, K, Nakagawa, Y, Ghulam Ali, S, Fusini, L, Tamborini, G, Muratori, M, Gripari, P, Bottari, V, Celeste, F, Cefalu', C, Alamanni, F, Pepi, M, Obase, K, Mor-Avi, V, Weinert, L, Lang, R, Teixeira, R, Monteiro, R, Garcia, J, Ribeiro, M, Cardim, N, Goncalves, L, Miglioranza, MH, Muraru, D, Cavalli, G, Addetia, K, Cucchini, U, Mihaila, S, Tadic, M, Veronesi, F, Lang, RM, Badano, L, Galian Gay, L, Gonzalez Alujas, MT, Teixido Tura, G, Gutierrez Garcia, L, Rodriguez-Palomares, JF, Evangelista Masip, A, Conte, L, Fabiani, I, Giannini, C, La Carruba, S, De Carlo, M, Barletta, V, Petronio, AS, Di Bello, V, Mahmoud, H, Al-Ghamdi, M, Ghabashi, A, Salaun, E, Zenses, AS, Evin, M, Collart, F, Pibarot, P, Habib, G, Rieu, R, Fabregat Andres, O, Estornell Erill, J, Cubillos-Arango, A, Bochard-Villanueva, B, Chacon-Hernandez, N, Higueras-Ortega, L, Perez-Bosca, L, Paya-Serrano, R, Ridocci-Soriano, F, Cortijo-Gimeno, J, Mzoughi, K, Zairi, I, Jabeur, M, Ben Moussa, F, Mrabet, K, Kamoun, S, Fennira, S, Ben Chaabene, A, Kraiem, S, Schnell, F, Betancur, J, Daudin, M, Simon, A, Lentz, PA, Tavard, F, Hernandes, A, Carre, F, Garreau, M, Donal, E, Abduch, MCD, Vieira, MLC, Antunes, M, Mathias, W, Mady, C, Arteaga, E, Alencar, AM, Tesic, M, Djordjevic-Dikic, A, Beleslin, B, Giga, V, Trifunovic, D, Petrovic, O, Jovanovic, I, Petrovic, M, Stepanovic, J, Vujisic-Tesic, B, Choi, EY, Cha, JJ, Chung, H, Kim, KH, Yoon, YW, Kim, JY, Lee, BK, Hong, BK, Rim, SJ, Kwon, HM, Bergler-Klein, J, Geier, C, Maurer, G, Gyongyosi, M, Cortes Garcia, M, Oliva, MR, Navas, MA, Orejas, M, Rabago, R, Martinez, ME, Briongos, S, Romero, AM, Rey, M, Farre, J, Ruisanchez Villar, C, Ruiz Guerrero, L, Rubio Ruiz, S, Lerena Saenz, P, Gonzalez Vilchez, FJ, Hernandez Hernandez, JL, Armesto Alonso, S, Blanco Alonso, R, Martin Duran, R, Gonzalez-Gay, MA, Novo, G, Marturana, I, Bonomo, V, Arvigo, L, Evola, V, Karfakis, G, Lo Presti, M, Verga, S, Novo, S, Petroni, R, Acitelli, A, Bencivenga, S, Cicconetti, M, Di Mauro, M, Petroni, A, Romano, S, Penco, M, Park, SM, Kim, SA, Kim, MN, Shim, WJ, Tadic, M, Majstorovic, AM, Ivanovic, BI, Celic, VC, Driessen, M M P, Meijboom, FJ, Mertens, L, Dragulescu, A, Friedberg, MK, De Stefano, F, Santoro, C, Buonauro, A, Muscariello, R, Lo Iudice, F, Ierano, P, Esposito, R, Galderisi, M, Sunbul, M, Kivrak, T, Durmus, E, Yildizeli, B, Mutlu, B, Rodrigues, AC, Daminello, E, Echenique, LS, Cordovil, A, Oliveira, W, Monaco, CH, Lira, E, Fischer, CH, Vieira, M, Morhy, S, Mignot, A, Jaussaud, J, Chevalier, L, Lafitte, S, D'ascenzi, F, Cameli, M, Curci, V, Alvino, F, Lisi, M, Focardi, M, Corrado, D, Bonifazi, M, Mondillo, S, Ikonomidis, I, Pavlidis, G, Lambadiari, V, Kousathana, F, Triantafyllidi, H, Varoudi, M, Dimitriadis, G, Lekakis, J, Cho, J S, Cho, EJ, Yoon, HJ, Ihm, SH, Lee, JH, Molnar, A A, Kovacs, A, Apor, A, Tarnoki, AD, Tarnoki, DL, Horvath, T, Maurovich-Horvat, P, Jermendy, GY, Kiss, RG, Merkely, B, Al-Habbaa, A, Petrovic-Nagorni, S, Ciric-Zdravkovic, S, Stanojevic, D, Jankovic-Tomasevic, R, Atanaskovic, V, Mitic, V, Todorovic, L, Dakic, S, Park, J S, Choi, JH, Kim, SH, Choi, JH, Kwon, YS, Jin, HY, Coppola, C, Piscopo, G, Galletta, F, Maurea, C, Esposito, E, Barbieri, A, Maurea, N, Kaldararova, M, Tittel, P, Kantorova, A, Vrsanska, V, Kollarova, E, Hraska, V, Nosal, M, Ondriska, M, Masura, J, Simkova, I, Tadeu, I, Azevedo, O, Lourenco, M, Luis, F, Lourenco, A, Planinc, i, Bagadur, G, Bijnens, B, Ljubas, J, Baricevic, Z, Skoric, B, Velagic, V, Milicic, D, Cikes, M, Campanale, C M, Di Maria, S, Mega, S, Nusca, A, Marullo, F, Di Sciascio, G, El Tahlawi, M, Abdallah, M, Gouda, M, Gad, MARWA, Elawady, M, Igual Munoz, B, Maceira Gonzalez Alicia, AMG, Estornell Erill, JEE, Donate Betolin, LDB, Vazquez Sanchez Alejandro, AVS, Valera Martinez, FVM, Sepulveda- Sanchez, PSS, Cervera Zamora, ACZ, Piquer Gil Marina, MPG, Montero- Argudo, AMA, Naka, KK, Evangelou, D, Lakkas, L, Kalaitzidis, R, Bechlioulis, A, Gkirdis, I, Tzeltzes, G, Nakas, G, Pappas, K, Michalis, LK, Mansencal, N, Bagate, F, Arslan, M, Siam-Tsieu, V, Deblaise, J, El Mahmoud, R, Dubourg, O, Wierzbowska-Drabik, K, Plewka, M, Kasprzak, JD, Bandera, F, Generati, G, Pellegrino, M, Alfonzetti, E, Labate, V, Villani, S, Gaeta, M, Guazzi, M, Bandera, F, Generati, G, Pellegrino, M, Labate, V, Alfonzetti, E, Guazzi, M, Generati, G, Bandera, F, Pellegrino, M, Labate, V, Alfonzetti, E, Guazzi, M, Grycewicz, T, Szymanska, K, Grabowicz, W, Lubinski, A, Sotaquira, M, Pepi, M, Tamborini, G, Caiani, EG, Bochard Villanueva, B, Chacon-Hernandez, N, Fabregat-Andres, O, Garcia-Gonzalez, P, Cubillos-Arango, A, De La Espriella-Juan, R, Albiach-Montanana, C, Berenguer-Jofresa, A, Perez-Bosca, JL, Paya-Serrano, R, Cheng, H-L, Huang, C-H, Wang, Y-C, Chou, W-H, Kuznetsov, VA, Melnikov, NN, Krinochkin, DV, Kolunin, GV, Enina, TN, Sierraalta, W, Le Bihan, D, Barretto, RBM, Assef, JE, Gospos, M, Buffon, M, Ramos, AIO, Garcia, A, Pinto, IMF, Souza, AGMR, Mueller, H, Reverdin, S, Ehret, G, Conti, L, Dos Santos, S, Abdel Moneim, S S, Nhola, L F, Huang, R, Kohli, M, Longenbach, S, Green, M, Villarraga, H R, Bordun, K A, Jassal, D S, Mulvagh, S L, Evangelista, A, Madeo, A, Piras, P, Giordano, F, Giura, G, Teresi, L, Gabriele, S, Re, F, Puddu, P, Torromeo, C, Suwannaphong, S, Vathesatogkit, P, See, O, Yamwong, S, Katekao, W, Sritara, P, Iliuta, L, Szulik, M, Streb, W, Wozniak, A, Lenarczyk, R, Sliwinska, A, Kalarus, Z, Kukulski, T, Weng, K-P, Lin, C-C, Hein, S, Lehmann, L, Kossack, M, Juergensen, L, Katus, HA, Hassel, D, Turrini, F, Scarlini, S, Giovanardi, P, Messora, R, Mannucci, C, Bondi, M, Olander, R, Sundholm, JKM, Ojala, TH, Andersson, S, Sarkola, T, Karolyi, M, Kocsmar, I, Raaijmakers, R, Kitslaar, PH, Horvath, T, Szilveszter, B, Merkely, B, Maurovich-Horvat, P, Heart, Center, Vascular, University, Semmelweis, Budapest, Hungary, and Group, MTA-SE Lendület Cardiovascular Imaging Research

Abstract

Purpose: Although delayed-enhancement magnetic resonance imaging (DEMRI) is essential for diagnosis of cardiac sarcoidosis (CS), the test was not available when pacemaker was implamted. Recently, MR-conditional pacemaker has become avilable and we hypothesized that this device would be useful for diagnosis and management of CS. The aim of this study was to assess the diagnostic ability of MR-conditional pacemaker about CS in patients with advanced A-V nodal block (AAVB). Methods: Twenty-seven AAVB patients (14 men, 13 women; mean age, 69 ± 11 years) who were implanted MR-conditional pacemaker were studied. DEMRI was performed 6 weeks after implantation of permanent pacemaker. In patients with positive for DE, additional examinations like echocardiography, radioisotope imaging, biopsy, and coronary computed-tomography were performed due to confirm the diagnosis of CS and exclude coronary artery disease. Results: DE was observed in 12 patients (44 %). Out of 12 patients, 2 patients were excluded for having prior myocardial infarction. Seven of 10 (70 %) patients were diagnosed of CS by the consensus criteria. Compared with non-CS group, CS group had significantly lower age (61 ± 12 years vs. 72 ± 9 years p = 0.017). There was no significant difference about sex, angiotensin-converting enzyme, brain natriuretic peptide, and left ventricular ejection fraction between 2 groups. Six patients had started corticosteroid therapy and 5 patients (83%) recovered A-V nodal conduction. Conclusion: MR-conditional pacemaker was useful for diagnosis and management of patients with AAVB caused by CS. Figure Cardiac MRI in patient with AV block

Published
2014
Full Text
View/download PDF

4. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials.

Author

Furtado RHM, Barros E Silva PGM, Fonseca HAR, Serpa-Neto A, Correa TD, Guimarães HP, Pereira AJ, Olivato GB, Zampieri FG, Lisboa T, Junqueira DLM, Lapa MG, Monfardini F, Damiani LP, Echenique LS, Gebara OE, Hoffman Filho CR, Polanczyk CA, Rohde LE, Amazonas R, Machado FR, Avezum A, Azevedo LCP, Veiga VC, Rosa RG, Lopes RD, Cavalcanti AB, and Berwanger O

Subjects
Humans, Arrhythmias, Cardiac chemically induced, Arrhythmias, Cardiac epidemiology, Arrhythmias, Cardiac drug therapy, Azithromycin adverse effects, COVID-19 Drug Treatment, Electrocardiography methods, Hydroxychloroquine therapeutic use, Randomized Controlled Trials as Topic, SARS-CoV-2, COVID-19, Long QT Syndrome chemically induced
Abstract

The cardiovascular safety from azithromycin in the treatment of several infectious diseases has been challenged. In this prespecified pooled analysis of 2 multicenter randomized clinical trials, we aimed to assess whether the use of azithromycin might lead to corrected QT (QTc) interval prolongation or clinically relevant ventricular arrhythmias. In the COALITION COVID Brazil I trial, 667 patients admitted with moderate COVID-19 were randomly allocated to hydroxychloroquine, hydroxychloroquine plus azithromycin, or standard of care. In the COALITION COVID Brazil II trial, 447 patients with severe COVID-19 were randomly allocated to hydroxychloroquine alone versus hydroxychloroquine plus azithromycin. The principal end point for the present analysis was the composite of death, resuscitated cardiac arrest, or ventricular arrhythmias. The addition of azithromycin to hydroxychloroquine did not result in any prolongation of the QTc interval (425.8 ± 3.6 ms vs 427.9 ± 3.9 ms, respectively, mean difference -2.1 ms, 95% confidence interval -12.5 to 8.4 ms, p = 0.70). The combination of azithromycin plus hydroxychloroquine compared with hydroxychloroquine alone did not result in increased risk of the primary end point (proportion of patients with events at 15 days 17.2% vs 16.0%, respectively, hazard ratio 1.08, 95% confidence interval 0.78 to 1.49, p = 0.65). In conclusion, in patients hospitalized with COVID-19 already receiving standard-of-care management (including hydroxychloroquine), the addition of azithromycin did not result in the prolongation of the QTc interval or increase in cardiovascular adverse events. Because azithromycin is among the most commonly prescribed antimicrobial agents, our results may inform clinical practice. Clinical Trial Registration: NCT04322123, NCT04321278., Competing Interests: Declaration of competing interest Dr. Furtado reports research grants and personal fees from AstraZeneca, Bayer, Servier, and Apsen and research grants (received from his institution) from Pfizer, Libbs, Brazilian Ministry of Health, and University Health Network. Dr. Fonseca received research grants from AstraZeneca, Pfizer, Essity, Aché, Colgate, BioGen, and Brazilian Ministry of Health. Dr. Barros e Silva reports reports fees and research grants from Pfizer, Roche Diagnostics, and Bayer. Dr. Pereira reports research grants from Brazilian Ministry of Health through PROADI-SUS Program (not related to this article). Dr. Polanczyk received research grants and professional fees from AstraZeneca, Bayer, Pfizer, Novartis, Roche, Sanofi, and Brazilian Ministry of Health through PROADI Programs. Dr. Veiga received grants from Brazilian Ministry of Health through PROADI-SUS Program. Dr. Rosa received research grants from Pfizer, Merck Sharp & Dohme, and Brazilian Ministry of Health. Dr. Azevedo received professional fees from Baxter, Nestle, and Merck Sharp & Dohme not related to the present work and research grants from Brazilian Ministry of Health through PROADI-SUS Program. Dr. Avezum reports research grants from Bayer, Sanofi-Pasteur, and Population Health Research Institute. Dr. Cavalcanti reports research grants from Bayer. Dr. Lopes reports research support from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer and consulting fees from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, and Portola. Dr. Berwanger report research grants from Bayer, Pfizer, AstraZeneca, Servier, Novartis, and Boehringer-Ingelheim. The remaining authors have no competing interest to declare., (Copyright © 2023 Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

5. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.

Author

Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros E Silva PGM, Tramujas L, Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, Machado FR, and Berwanger O

Subjects
Adult, Aged, Aged, 80 and over, Antiviral Agents therapeutic use, Azithromycin therapeutic use, Betacoronavirus, Brazil, COVID-19, Drug Therapy, Combination, Female, Hospitalization, Humans, Hydroxychloroquine therapeutic use, Male, Middle Aged, Pandemics, Patient Acuity, SARS-CoV-2, Treatment Failure, COVID-19 Drug Treatment, Antiviral Agents administration & dosage, Azithromycin administration & dosage, Coronavirus Infections drug therapy, Hydroxychloroquine administration & dosage, Pneumonia, Viral drug therapy
Abstract

Background: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited., Methods: We conducted a multicenter, randomized, open-label, three-group, controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen. Patients were randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days. The primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale (with levels ranging from one to seven and higher scores indicating a worse condition) in the modified intention-to-treat population (patients with a confirmed diagnosis of Covid-19). Safety was also assessed., Results: A total of 667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis. As compared with standard care, the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confidence interval [CI], 0.69 to 2.11; P = 1.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99; 95% CI, 0.57 to 1.73; P = 1.00). Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent., Conclusions: Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. (Funded by the Coalition Covid-19 Brazil and EMS Pharma; ClinicalTrials.gov number, NCT04322123.)., (Copyright © 2020 Massachusetts Medical Society.)

Published
2020
Full Text
View/download PDF

7. Left ventricular noncompaction in a Para athlete.

Author

Maia EC, Savioli FA, Pinheiro SR, Echenique LS, and Oliveira Filho JA

Subjects
Adolescent, Arrhythmias, Cardiac complications, Asymptomatic Diseases, Athletes, Electrocardiography, Exercise, Female, Humans, Isolated Noncompaction of the Ventricular Myocardium complications, Magnetic Resonance Imaging, Nystagmus, Congenital complications, Isolated Noncompaction of the Ventricular Myocardium diagnostic imaging
Abstract

The left ventricular noncompaction is a congenital cardiomyopathy characterized by the presence of abnormal trabeculations in the left ventricle. The present study describes the case of a 14-year-old female Para athlete, who plays goalball. She was asymptomatic, with history of congenital nystagmus and mild visual impairment, who presented nonspecific electrocardiographic abnormalities during pre-competition screening. Cardiac magnetic resonance imaging showed left ventricular non-compaction (non-compacted to compacted layer ratio equal to 2.5) and mild biventricular systolic dysfunction. Initially, the patient was excluded from sports participation and clinical follow-up was performed every three months. Patient remained asymptomatic during the one-year follow-up, with no history of unexplained syncope, marked impairment of systolic function or significant ventricular arrhythmias at the exercise stress test. Finally, she was released for competitive goalball participation and clinical follow-up was continued every 6 months. There is no consensus regarding the eligibility criteria for sports participation in cases of left ventricular non-compaction. Thus, it is prudent to individualize the decision regarding practice of sports, as well as to consider participation in competitive sports for asymptomatic individuals and with no disease repercussions.

Published
2019
Full Text
View/download PDF

8. Athlete's heart in a Brazilian paralympic judo team. Case series study.

Author

Oliveira Filho JA, Barros MBM, Salles AF, Echenique LS, Campos Filho O, and Póvoa RMS

Subjects
Adult, Brazil, Echocardiography, Electrocardiography, Exercise Test, Female, Humans, Male, Observer Variation, Cardiomegaly, Exercise-Induced physiology, Martial Arts statistics & numerical data, Oxygen Consumption physiology
Abstract

Background: Athlete's heart is a term describing the cardiovascular effects of long-term conditioning among highly trained athletes. It is a variation of normal standards., Design and Setting: Case series study at the cardiology division of a public university hospital., Methods: We studied 14 visually handicapped paralympic athletes (8 men) in the national judo team. They were 26.3 ± 6.4 years old, with body mass index 25 ± 14, and had been practicing judo for 9.2 ± 7.9 years. Clinical evaluations, electrocardiograms, exercise testing and echocardiograms were performed by independent observers., Results: Signs of athlete's heart were found in all athletes, comprising left ventricular hypertrophy (5 cases), sinus bradycardia (5), T-wave juvenile pattern (3), T wave juvenile pattern (3), left atrial hypertrophy (2) and increased left ventricular volume (9 cases; 62.22 ± 6.46 ml/m2). There were very strong correlations between left ventricular mass/body surface and endurance time (r: 0.91) and estimated peak oxygen uptake (r: 0.8). The correlations between left ventricular internal diastolic dimension and endurance time (r: 0.91) and estimated peak oxygen uptake (r: 0.8) were strong. Despite increased left ventricular dimensions (4 cases), atrial dimensions (1) and relative wall thickness (4), all athletes had normal left ventricular mass/body surface (89.98 ± 21.93 g/m²). The exercise testing was normal: exercise duration 706 ± 45 seconds and estimated peak oxygen uptake 62.70 ± 9.99 mlO2/min., Conclusions: Signs of athlete's heart were seen frequently in the paralympic judo team. These demonstrated the presence of mild cardiac adaptations to training.

Published
2018
Full Text
View/download PDF

9. Thoracoscopic esophagectomy in children.

Author

Cury EK, Schraibman V, De Vasconcelos Macedo AL, and Echenique LS

Subjects
Accidents, Home, Burns, Chemical etiology, Child, Child, Preschool, Esophagus surgery, Female, Follow-Up Studies, Humans, Male, Minimally Invasive Surgical Procedures methods, Thoracic Surgery, Video-Assisted methods, Thyroglossal Cyst diagnosis, Treatment Outcome, Burns, Chemical surgery, Caustics adverse effects, Esophagectomy methods, Esophagus injuries, Thoracoscopy methods, Thyroglossal Cyst surgery
Abstract

Minimal access surgery is an alternative to open surgery in esophageal resections. Thoracoscopic surgery has been utilized for both benign and malignant esophageal lesions and is a complex and challenging surgical procedure that can provide some benefits in comparison with open thoracotomy. Many studies have described laparoscopic or thoracoscopic-assisted esophagectomy in adults. So far, to the best of our knowledge, there is no study about thoracoscopic esophagectomy in children. This report describes 2 pediatric cases of benign esophageal lesions: one stricture after accidental ingestion of caustic soda and one esophageal stenosis after thyroglossal duct complication. Both patients were submitted to thoracoscopic esophagectomy combined with laparotomy and open cervical exploration with success. This procedure presents some potential advantages when compared with open esophagectomy: shorter hospital stay, precise dissection of mediastinal structures, less postoperative pain, less blood loss during surgery and less long-term discomfort. In our cases, thoracoscopic surgery for children showed the same benefits as in adults. Although very feasible, it should not be attempted without sufficient training and should be carried out only in specialized medical centers and by surgeons with adequate experience with open esophagectomy., (Copyright 2001 by W.B. Saunders Company.)

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results